EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors

Valeria Lucarini, Ombretta Melaiu, Paula Gragera iD, Kamila Król, Valentina Scaldaferri iD, Verena Damiani iD, Adele De Ninno iD, Daniela Nardozi iD, Luca Businaro iD, Laura Masuelli, Roberto Bei iD, Loredana Cifaldi iD und 1 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26041613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Valeria Lucarini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy. Hauptthemen laut MEDLINE: Immunogenic Cell Death, Immunotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Associazione Italiana Ricerca sul Cancro (AIRC), Italian Ministry of Health with Ricerca Finalizzata.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of chemotherapeutic agents with immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment. However, its success is often limited by insufficient immune priming in certain tumors, including pediatric malignancies. In this report, we explore clinical trials currently investigating the use of immunogenic cell death (ICD)-inducing chemotherapies in combination with ICIs for both adult and pediatric cancers. Given the limited clinical data available for pediatric tumors, we focused on recent preclinical studies evaluating the efficacy of these combinations in neuroblastoma (NB). Finally, to address this gap, we propose an innovative strategy to assess the impact of ICD-inducing chemotherapies on antitumor immune responses in NB. Using tumor spheroids derived from a transgenic NB mouse model, we validated our previous in vivo findings concerning how anthracyclines, specifically mitoxantrone and doxorubicin, significantly enhance MHC class I surface expression, stimulate IFNγ and granzyme B production by CD8+ T cells and NK cells, and promote immune cell recruitment. Importantly, these anthracyclines also upregulated PD-L1 expression on NB spheroids. This screening platform yielded results similar to in vivo findings, demonstrating that mitoxantrone and doxorubicin are the most potent immunomodulatory agents for NB. These data suggest that the creation of libraries of ICD inducers to be tested on tumor spheroids could reduce the number of combinations to be tested in vivo, in line with the principles of the 3Rs. Furthermore, these results highlight the potential of chemo-immunotherapy regimens to counteract the immunosuppressive tumor microenvironment in NB, paving the way for improved therapeutic strategies in pediatric cancers. They provide compelling evidence to support further clinical investigations of these combinations to enhance outcomes for children with malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunogenic Cell DeathImmunotherapyAnimalsHumansMiceCD8-Positive T-LymphocytesDoxorubicinImmune Checkpoint InhibitorsMitoxantroneNeoplasmsNeuroblastomaSpheroids, Cellular

Stichwörter der Autor:innen

anthracyclinesimmune checkpoint inhibitorsimmunogenic cell deathneuroblastomapediatric cancertumor microenvironmenttumor spheroids

Substanzen

DoxorubicinImmune Checkpoint InhibitorsMitoxantrone

Autor:innen und Institutionen

  • Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Department of Experimental Medicine, University of Rome "Sapienza", 00161 Rome, Italy.
  • Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
  • Institute for Photonics and Nanotechnologies, National Research Council, Via Fosso del Cavaliere, 00133 Rome, Italy.

ORCID-Profile: Paula Gragera, Valentina Scaldaferri, Verena Damiani, Adele De Ninno, Daniela Nardozi, Luca Businaro, Roberto Bei, Loredana Cifaldi, Doriana Fruci

Förderung

  • Italian Association for Cancer Research
  • Associazione Italiana Ricerca sul Cancro (AIRC)
  • Italian Ministry of Health with Ricerca Finalizzata
  • European Union’s Horizon 2020 research and Innovation program
  • Fondazione Umberto Veronesi (FUV)
  • CAPSTONE-ETN H2020 Early Stage Researchers

Zitieren

APA

Lucarini, V., Melaiu, O., Gragera, P., Król, K., Scaldaferri, V., Damiani, V., De Ninno, A., Nardozi, D., Businaro, L., Masuelli, L., Bei, R., Cifaldi, L., & Fruci, D. (2025). Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041613

Vancouver

Lucarini V, Melaiu O, Gragera P, Król K, Scaldaferri V, Damiani V, et al. Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041613

BibTeX
@article{Lucarini2025,
  author = {Lucarini, Valeria and Melaiu, Ombretta and Gragera, Paula and Król, Kamila and Scaldaferri, Valentina and Damiani, Verena and De Ninno, Adele and Nardozi, Daniela and Businaro, Luca and Masuelli, Laura and Bei, Roberto and Cifaldi, Loredana and Fruci, Doriana},
  title = {Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26041613}
}
Kostenlos starten →